Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


According to the National Cancer Institute, Colorectal cancer (CRC) is the third most common non-skin cancer in men and women in the U.S. and the second leading cause of cancer-related death. In the last 10 years the number of disease-related deaths have declined, partly due to more frequent screenings. On September 22nd the U.S. FDA approved Lonsurf for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.

Read more

A team of researchers from the Ludwig Center at Stanford University School of Medicine in California engineered a small molecule with high affinity for PDL-1 that was found to be a more effective anticancer immunotherapeutic than conventional anti-PD-L1 antibodies. The team presented their findings at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, held September 16-19.

Read more

Selectively targeting cancer cells sparing the normal organs is a major challenge in oncology drug discovery. Paramount efforts are continuously made to find new anticancer agents that can reduce the physical toll associated with cancer treatment. Scientists at the University of Virginia School of Medicine discovered a new link between cancer cells and developing oocytes, the original cell from which all the tissues in the body derive, that could become a frontline treatment for women who have cancers of many types and want to preserve fertility.

Read more

The American Cancer Society, in citing a study published in the Journal of the National Cancer Institute, suggests that low-dose of a the common aspirin could be useful in treating and preventing recurrence of several types of cancer, including esophageal, ovarian, stomach and prostate cancer. A new study published on Cell by Professor Caetano Reis e Sousa’s research group at The Francis Crick Institute suggests that aspirin could benefit cancer patients by boosting their immune system, rather than actively killing cancer cells.

Read more

Despite significant progress made over the last 20 years, colorectal cancer (CRC) is still a leading cause of cancer-related death worldwide. Improved preclinical models that will help precision medicine become a reality for patients with CRC and identify biomarkers of response are urgently needed. A team of researcher at the University of Wisconsin Carbone Cancer Center developed new preclinical models for CRC that will help to identify the patients population that will most likely benefit from new therapies.

Read more